NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection.
作者信息
Vohra-Miller Sabina, Schwartz Ilan S
机构信息
Division of Clinical Public Health (Vohra-Miller), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.; Division of Infectious Diseases (Schwartz), Department of Medicine, Duke University, Durham, NC.
出版信息
CMAJ. 2022 Sep 12;194(35):E1214. doi: 10.1503/cmaj.220688.
Abstract
摘要
相似文献
1
NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection.NVX-CoV2373，一种针对新型冠状病毒感染的基于蛋白质的疫苗。
CMAJ. 2022 Sep 12;194(35):E1214. doi: 10.1503/cmaj.220688.
2
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.SARS-CoV-2 刺突糖蛋白疫苗候选物 NVX-CoV2373 在食蟹猴中的免疫原性和在小鼠中的保护作用。
Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.
3
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.不同剂量方案的新型冠状病毒重组刺突蛋白疫苗（NVX-CoV2373）在年轻和老年成年人中的效果：一项 2 期随机安慰剂对照试验。
PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct.
4
Protein vaccine NVX-CoV2373 elicits functional T cell immunity.蛋白疫苗 NVX-CoV2373 可诱导功能性 T 细胞免疫。
J Clin Invest. 2022 Oct 3;132(19):e163614. doi: 10.1172/JCI163614.
5
Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.社论：首款基于蛋白的佐剂 Novavax 疫苗 Nuvaxovid（NVX-CoV2373）获批用于 SARS-CoV-2，有望提高疫苗接种率，并提供针对病毒变异株的免疫保护。
Med Sci Monit. 2022 Mar 1;28:e936523. doi: 10.12659/MSM.936523.
6
NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.接种 NVX-CoV2373 可诱导产生针对 SARS-CoV-2 的功能性 CD4+ 和 CD8+ T 细胞应答。
J Clin Invest. 2022 Oct 3;132(19):e160898. doi: 10.1172/JCI160898.
7
Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.下一代新冠疫苗：疫苗研发机遇与应对新冠疫情的挑战
Drug Discov Ther. 2021;15(3):118-123. doi: 10.5582/ddt.2021.01058.
8
NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression.NVX-Cov2373 诺瓦瓦克斯新冠病毒疫苗：使用多种表达模式对其疗效的进一步分析。
Fundam Clin Pharmacol. 2022 Dec;36(6):1125-1127. doi: 10.1111/fcp.12794. Epub 2022 May 7.
9
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.通过临床终点预测疫苗诱导的中和抗体的长期动力学和针对 SARS-CoV-2 Delta 变异株的时变疫苗特异性疗效。
BMC Med. 2022 Jan 28;20(1):36. doi: 10.1186/s12916-022-02249-9.
10
Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.接种 SARS-CoV-2 疫苗后出现横贯性脊髓炎：世界卫生组织数据库中的药物流行病学研究。
Ann Neurol. 2022 Dec;92(6):1080-1089. doi: 10.1002/ana.26494. Epub 2022 Sep 23.
引用本文的文献
1
Combination Adjuvants Enhance Recombinant H5 Hemagglutinin Vaccine Protection Against High-Dose Viral Challenge in Chickens.联合佐剂增强重组H5血凝素疫苗对鸡高剂量病毒攻击的保护作用。
Vaccines (Basel). 2024 Dec 23;12(12):1448. doi: 10.3390/vaccines12121448.
2
Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies.新型冠状病毒（SARS-CoV-2）的突变动态：对未来新冠疫苗策略的影响
Heliyon. 2024 Apr 25;10(9):e30208. doi: 10.1016/j.heliyon.2024.e30208. eCollection 2024 May 15.
3
Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins.基于外泌体的多价疫苗：用纳克级蛋白质实现有效的免疫接种、广泛的反应性和强烈的 T 细胞反应。
Microbiol Spectr. 2023 Jun 15;11(3):e0050323. doi: 10.1128/spectrum.00503-23. Epub 2023 Apr 24.
4
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.新冠疫苗平台概述，重点介绍亚单位疫苗。
Prog Biophys Mol Biol. 2023 Mar;178:32-49. doi: 10.1016/j.pbiomolbio.2023.02.004. Epub 2023 Feb 18.
本文引用的文献
1
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.NVX-CoV2373 在美墨成年人群中的疗效和安全性。
N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15.
2
How protein-based COVID vaccines could change the pandemic.基于蛋白质的新冠疫苗如何改变这场大流行。
Nature. 2021 Nov;599(7885):359-360. doi: 10.1038/d41586-021-03025-0.
3
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.新型冠状病毒疫苗 NVX-CoV2373 的安全性和有效性。
N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30.
Zotero 插件